Eli Lilly Smashes Views On Back Of Mounjaro, Zepbound

Pharmaceutical giant Eli Lilly (LLY) significantly exceeded third-quarter earnings and revenue expectations, propelled by exceptional sales of its diabetes and obesity treatments, Mounjaro ($6.52 billion) and Zepbound ($3.59 billion), leading to a substantial increase in its full-year financial outlook. The company reported a 495% surge in adjusted EPS to $7.02 and a 54% rise in sales to $17.6 billion, causing its stock to climb. Despite this strong performance and a promising pipeline, analysts caution that potential overhangs from Medicare pricing negotiations, particularly regarding rival GLP-1 drugs, and "Most Favored Nation" drug price discussions could impact future share performance.

Analysis

Eli Lilly (LLY) significantly surpassed third-quarter expectations, reporting adjusted earnings per share of $7.02, a 495% year-over-year increase, and sales of $17.6 billion, up 54%, both handily beating analyst forecasts. This robust performance was primarily driven by its diabetes and obesity treatments, with Mounjaro sales more than doubling to $6.52 billion and Zepbound sales rocketing 185% to $3.59 billion, both exceeding bullish projections. Consequently, the company raised its full-year adjusted profit outlook to $23-$23.70 per share and sales guidance to $63-$63.5 billion, representing a $2.25 billion increase from its previous sales view.

Analysts view this as an exceptionally strong quarter, with Cantor's Carter Gould calling it "arguably the strongest print across 3Q so far" and highlighting the $2.25 billion top-line guidance raise as particularly impressive, suggesting further potential upside. Edward Jones analyst John Boylan anticipates continued strong demand for Mounjaro and Zepbound, reinforcing the positive trajectory for Lilly's key growth drivers. The stock reacted positively, rising over 1% post-announcement.

Despite the strong operational performance and optimistic outlook, potential macro issues present an overhang for LLY shares. Specifically, ongoing Medicare pricing negotiations involving rival GLP-1 drugs from Novo Nordisk (NVO) and broader "Most Favored Nation" drug price discussions with the Trump administration introduce regulatory uncertainty. These factors are expected to weigh on the stock until resolutions are achieved, as noted by analysts.

Key Decisions for Investors

• Investors should maintain a close watch on regulatory developments, specifically Medicare pricing negotiations and "Most Favored Nation" drug price discussions, as these represent key potential overhangs for LLY shares.
• Given the exceptional sales growth of Mounjaro and Zepbound and the raised full-year guidance, investors should assess the sustainability of demand for these blockbuster drugs and the potential of Lilly's pipeline assets to maintain market leadership.
• While operational performance is strong, investors should consider the stock's relative strength and technical indicators, as its low IBD Digital Relative Strength Rating suggests past underperformance despite recent positive news.